SCHEMBL3707667

SCHEMBL3707667

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccc(C(C)(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.60
ALOX15 P16050 4/20 0.59
LMNA P02545 1/20 0.59
ALDH1A1 P00352 7/20 0.59
HPGD P15428 2/20 0.59
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
TSHR P16473 2/20 0.55
POLB P06746 1/20 0.54
RXFP1 Q9HBX9 2/20 0.53
USP7 Q93009 1/20 0.53
MAPT P10636 1/20 0.53
HTT P42858 1/20 0.53
TP53 P04637 1/20 0.53
MDM2 Q00987 1/20 0.53
HSD17B10 Q99714 2/20 0.53
FPR1 P21462 1/20 0.50
GAA P10253 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
PPARG P37231 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715623 0.97 KDM4E (0.57) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3709475 0.90 KDM4E (0.59) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3705035 0.88 KDM4E (0.66) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3707576 0.87 KDM4E (0.64) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL16904821 0.87 KDM4E (0.64) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3705340 0.86 MEN1 (0.78) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3713778 0.86 KDM4E (0.63) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3706130 0.84 ALOX15 (0.62) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3709481 0.83 ALDH1A1 (0.66) KDM4EALOX15LMNAALDH1A1HPGD
SCHEMBL3710353 0.83 KDM4E (0.59) KDM4EALOX15LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed